AstraZeneca’s release Monday of encouraging data about its coronavirus vaccine from its U.S. trial raised hopes that the drug company could put a troubled rollout behind it. But just hours after its announcement, American officials issued an unusual statement expressing concern the company had included “outdated information” from its study and that it may have provided “an incomplete view of the efficacy data.”
Related posts
-
US markets tumble toward more big losses after China retaliates with an 84% tariff on US goods
U.S. stock futures were sinking again in premarket trading after massive U.S. tariffs against China kicked... -
Cubs refuse to hibernate in cold, beat Texas again
The Cubs should have a decided cold-weather advantage over a team like the Texas Rangers. On... -
Girls soccer: Stevenson’s stingy defense shuts down Hersey
Stevenson began a very busy week in style with a 2-0 victory in Arlington Heights over...